NasdaqGS - Nasdaq Real Time Price USD

Collegium Pharmaceutical, Inc. (COLL)

Compare
32.91
-0.43
(-1.29%)
At close: January 10 at 4:00:02 PM EST
31.89
-1.02
(-3.10%)
After hours: January 10 at 5:28:55 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
599,245.00
566,767.00
463,933.00
276,868.00
310,016.00
Cost of Revenue
225,559.00
240,598.00
254,445.00
126,251.00
130,180.00
Gross Profit
373,686.00
326,169.00
209,488.00
150,617.00
179,836.00
Operating Expense
180,214.00
159,208.00
176,169.00
128,411.00
123,604.00
Operating Income
193,472.00
166,961.00
33,319.00
22,206.00
56,232.00
Net Non Operating Interest Income Expense
-54,134.00
-67,724.00
-62,166.00
-21,002.00
-28,650.00
Other Income Expense
-11,329.00
-23,504.00
--
-4,578.00
--
Pretax Income
128,009.00
75,733.00
-28,847.00
-3,374.00
27,582.00
Tax Provision
39,415.00
27,578.00
-3,845.00
-74,891.00
830.00
Net Income Common Stockholders
88,594.00
48,155.00
-25,002.00
71,517.00
26,752.00
Average Dilution Earnings
10,247.00
5,889.00
--
4,675.00
--
Diluted NI Available to Com Stockholders
98,841.00
54,044.00
-25,002.00
76,192.00
26,752.00
Basic EPS
2.71
1.43
-0.74
2.05
0.78
Diluted EPS
2.34
1.29
-0.74
1.86
0.76
Basic Average Shares
32,325.90
33,741.21
33,829.50
34,936.82
34,407.96
Diluted Average Shares
45,726.62
41,788.13
33,829.50
41,045.81
35,151.35
Total Operating Income as Reported
193,472.00
166,961.00
33,319.00
17,628.00
56,232.00
Total Expenses
405,773.00
399,806.00
430,614.00
254,662.00
253,784.00
Net Income from Continuing & Discontinued Operation
88,594.00
48,155.00
-25,002.00
71,517.00
26,752.00
Normalized Income
96,434.71
63,103.54
-25,002.00
74,858.94
26,752.00
Interest Income
16,467.00
15,615.00
1,047.00
12.00
232.00
Interest Expense
70,601.00
83,339.00
63,213.00
21,014.00
28,882.00
Net Interest Income
-54,134.00
-67,724.00
-62,166.00
-21,002.00
-28,650.00
EBIT
198,610.00
159,072.00
34,366.00
17,640.00
56,464.00
EBITDA
346,721.00
308,328.00
173,305.00
86,557.00
118,014.00
Reconciled Cost of Revenue
225,559.00
240,598.00
254,445.00
126,251.00
130,180.00
Reconciled Depreciation
148,111.00
149,256.00
138,939.00
68,917.00
61,550.00
Net Income from Continuing Operation Net Minority Interest
88,594.00
48,155.00
-25,002.00
71,517.00
26,752.00
Total Unusual Items Excluding Goodwill
-11,329.00
-23,504.00
--
-4,578.00
--
Total Unusual Items
-11,329.00
-23,504.00
--
-4,578.00
--
Normalized EBITDA
358,050.00
331,832.00
173,305.00
91,135.00
118,014.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,488.29
-8,555.46
--
-1,236.06
--
12/31/2020 - 5/7/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCRX Pacira BioSciences, Inc.
20.64
+11.09%
 
BGM BGM Group Ltd.
11.35
-6.28%
 
KMDA Kamada Ltd.
7.41
+1.23%
 
AMPH Amphastar Pharmaceuticals, Inc.
36.36
-0.74%
 
SIGA SIGA Technologies, Inc.
6.21
-1.11%
 
PAHC Phibro Animal Health Corporation
20.05
-6.66%
 
ANIP ANI Pharmaceuticals, Inc.
55.04
+1.62%
 
SUPN Supernus Pharmaceuticals, Inc.
37.49
-1.50%
 
AVDL Avadel Pharmaceuticals plc
7.90
-26.10%
 
LFCR Lifecore Biomedical, Inc.
6.29
+8.45%